Gleason Briana C, Calder Kenneth B, Cibull Thomas L, Thomas Antoinette B, Billings Steven D, Morgan Michael B, Hiatt Kim M, Smoller Bruce R
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
J Cutan Pathol. 2009 May;36(5):543-7. doi: 10.1111/j.1600-0560.2008.01099.x. Epub 2009 Mar 30.
Atypical fibroxanthoma (AFX), spindle cell squamous cell carcinoma (SCSCC) and spindle cell melanoma are the primary entities in the differential diagnosis of a cytologically atypical spindle cell tumor arising on sun-damaged skin. AFX is generally regarded as a diagnosis of exclusion in this context: in the absence of S100 or keratin reactivity, a diagnosis of AFX is favored. However, keratin reactivity may be focal or even absent in SCSCC, and although numerous positive markers of AFX have been proposed, none has shown sufficient sensitivity and specificity for routine diagnostic use. We evaluated 20 AFX and 10 SCSCC with a panel of cytokeratins and p63 to assess the utility of the latter antibody in this differential diagnosis. All 10 SCSCC showed strong expression of p63, whereas all 20 AFX were p63 negative. Two additional cases (excluded from the study) were negative for keratins and S100 on initial shave biopsies, resulting in a favored diagnosis of AFX, but p63 stains performed retrospectively were positive. However, review of the excision specimens in both cases revealed deep subcutaneous extension, excluding AFX. p63 reactivity argues against the diagnosis of AFX and is therefore a useful addition to the standard immunohistochemical panel for cutaneous spindle cell neoplasms.
非典型纤维黄色瘤(AFX)、梭形细胞鳞状细胞癌(SCSCC)和梭形细胞黑色素瘤是鉴别诊断日光损伤皮肤中出现的细胞学非典型梭形细胞肿瘤的主要实体。在这种情况下,AFX通常被视为一种排除性诊断:在不存在S100或角蛋白反应性的情况下,倾向于诊断为AFX。然而,SCSCC中角蛋白反应性可能是局灶性的甚至不存在,并且尽管已经提出了许多AFX的阳性标志物,但没有一种标志物对常规诊断具有足够的敏感性和特异性。我们用一组细胞角蛋白和p63评估了20例AFX和10例SCSCC,以评估后一种抗体在这种鉴别诊断中的效用。所有10例SCSCC均显示p63强表达,而所有20例AFX均为p63阴性。另外2例(被排除在研究之外)在初次刮除活检时角蛋白和S100均为阴性,因此倾向于诊断为AFX,但回顾性进行的p63染色为阳性。然而,对这2例病例的切除标本进行复查发现有深部皮下浸润,排除了AFX。p63反应性不支持AFX的诊断,因此是皮肤梭形细胞肿瘤标准免疫组化检测项目中的一个有用补充。